Record #62807

Dual targeting of TGF-β and PD-L1 inhibits tumor growth in TGF-β/PD-L1-driven colorectal carcinoma

Publisher
Original paper date
Jun 30, 2023
Institution
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran · Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran · Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran · Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran · Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran · Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran · College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq · Australasian Nanoscience and Nanotechnology Initiative (ANNI), 8054 Monash University LPO, Clayton, Victoria, Australia · Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex, BN1 9PH, UK · School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, Brisbane, QLD, 4059, Australia · School of Mechanical, Medical and Process Engineering, Science and Engineering Faculty, Queensland University of Technology, 2 George St, Brisbane City QLD, 4000, Australia · Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia · Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam U.M.C., VU. University Medical Center (VUMC), Amsterdam, the Netherlands · Cancer Pharmacology Lab, AIRC Start up Unit, Fondazione Pisana per La Scienza, Pisa, Italy
Open access
No
Article type
Citation lifecycle

How this paper is being cited

Pre-retraction
9
Same day
0
Post-retraction
4
% post-retraction
30.8%
~6.5 citations/yr before retraction · ~2.2 citations/yr after
citing papers

Who is still citing this work

Loading…